Granahan Investment Management LLC Increases Holdings in Agios Pharmaceuticals, Inc. $AGIO

Key Points

• Granahan Investment Management LLC increased its stake in Agios Pharmaceuticals by 14.2%, holding 132,108 shares valued at approximately $3.87 million after an additional purchase during the first quarter.
• Agios Pharmaceuticals reported earnings of ($1.93) per share for the last quarter, missing analysts' expectations, but exceeded revenue estimates with $12.50 million in revenue.
• Several analysts have given mixed ratings on AGIO, with a consensus average target price of $56.00 and a mix of "buy" and "sell" ratings affecting investor sentiment.

Granahan Investment Management LLC increased its position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 14.2% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 132,108 shares of the biopharmaceutical company's stock after buying an additional 16,421 shares during the quarter. Granahan Investment Management LLC owned about 0.23% of Agios Pharmaceuticals worth $3,871,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Jefferies Financial Group Inc. purchased a new stake in shares of Agios Pharmaceuticals in the fourth quarter worth approximately $49,290,000. Adage Capital Partners GP L.L.C. increased its position in shares of Agios Pharmaceuticals by 145.2% during the first quarter. Adage Capital Partners GP L.L.C. now owns 743,000 shares of the biopharmaceutical company's stock valued at $21,770,000 after acquiring an additional 440,000 shares during the last quarter. Palo Alto Investors LP purchased a new stake in shares of Agios Pharmaceuticals during the first quarter valued at approximately $8,104,000. Paradigm Biocapital Advisors LP purchased a new stake in shares of Agios Pharmaceuticals during the fourth quarter valued at approximately $9,084,000. Finally, Deutsche Bank AG increased its position in shares of Agios Pharmaceuticals by 39.7% during the fourth quarter. Deutsche Bank AG now owns 935,252 shares of the biopharmaceutical company's stock valued at $30,732,000 after acquiring an additional 265,637 shares during the last quarter.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on AGIO shares. Wall Street Zen lowered Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Monday, May 19th. Scotiabank cut their price target on Agios Pharmaceuticals from $71.00 to $65.00 and set a "sector outperform" rating for the company in a report on Monday, July 28th. HC Wainwright reaffirmed a "buy" rating and issued a $56.00 price target on shares of Agios Pharmaceuticals in a report on Thursday, September 4th. Finally, Bank of America cut their price target on Agios Pharmaceuticals from $52.00 to $51.00 and set a "buy" rating for the company in a report on Tuesday, July 22nd. Six investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $56.00.

Agios Pharmaceuticals Stock Performance

Shares of AGIO traded down $0.26 during mid-day trading on Tuesday, reaching $36.15. The company had a trading volume of 616,336 shares, compared to its average volume of 722,992. The firm has a 50-day moving average price of $37.65 and a 200 day moving average price of $33.21. Agios Pharmaceuticals, Inc. has a 52 week low of $23.42 and a 52 week high of $62.58. The company has a market capitalization of $2.10 billion, a price-to-earnings ratio of 3.29 and a beta of 0.87.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last issued its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported ($1.93) EPS for the quarter, missing analysts' consensus estimates of ($1.74) by ($0.19). Agios Pharmaceuticals had a negative return on equity of 3.49% and a net margin of 1,590.42%.The company had revenue of $12.50 million during the quarter, compared to the consensus estimate of $9.46 million. As a group, research analysts forecast that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Agios Pharmaceuticals news, insider Sarah Gheuens sold 11,914 shares of the business's stock in a transaction on Wednesday, July 9th. The shares were sold at an average price of $37.99, for a total transaction of $452,612.86. Following the completion of the sale, the insider directly owned 61,271 shares in the company, valued at approximately $2,327,685.29. The trade was a 16.28% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Brian Goff sold 18,700 shares of the business's stock in a transaction on Tuesday, June 24th. The shares were sold at an average price of $33.54, for a total transaction of $627,198.00. Following the sale, the chief executive officer owned 105,401 shares of the company's stock, valued at approximately $3,535,149.54. This represents a 15.07% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 65,994 shares of company stock worth $2,341,232 in the last three months. Corporate insiders own 4.30% of the company's stock.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.